CYTOKINE RELEASE SYNDROME IN ONCOLOGIC PATIENTS TREATED WITH CAR-T

Опубликована: Авг. 26, 2024

Background: The development and use of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), has transformed cancer treatment. However, managing related toxicities remains a significant challenge. Objectives: To provide an overview cytokine release syndrome (CRS) in patients receiving CAR-T treatment, focusing on its clinical therapeutic management. Methods: A literature review was conducted to gather current knowledge insights CRS associated with therapy. Sources included peer-reviewed journals, studies, expert reviews. Results: Prevalence CRS: is common toxicity therapy, variable incidence depending the type product used patient-specific factors. Clinical Presentation: can range from mild flu-like symptoms severe, life-threatening manifestations, including high fever, hypotension, multi-organ dysfunction. Challenges Identification: Differentiating other conditions such as sepsis challenging due overlapping features. Therapeutic Management: Management strategies include supportive care, corticosteroids, inhibitors like tocilizumab. Early recognition intervention are critical improve patient outcomes. Conclusion: Effective management cell therapy vital mitigate potentially fatal consequences. Continued research vigilance essential for improving safety efficacy treatments patients.

Язык: Английский

Cellular Therapies for Multiple Myeloma: Engineering Hope

Cancers, Год журнала: 2024, Номер 16(22), С. 3867 - 3867

Опубликована: Ноя. 19, 2024

Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell maturation (BCMA), mark a major breakthrough, achieving long-lasting remissions instilling hope for potential cure. While ongoing clinical trials are increasingly driving approved cellular products towards earlier lines of therapy, novel targets advanced approaches employing natural killer (NK) or dendritic (DC) vaccines currently under investigation. Treatment resistance, driven by tumor-intrinsic factors such escape the intricate dynamics tumor microenvironment (TME), along with emerging side effects movement neurocognitive treatment-emergent adverse events (MNTs), limitations therapies. To improve efficacy overcome cutting-edge research is exploring strategies target synergistic combinatorial approaches. Recent advances in CAR-T production involve shortened manufacturing protocols "off-the-shelf" cells, aiming at decreasing socioeconomic barriers thereby increasing patient access this lifesaving therapy. In review, we provide an extensive overview evolving field therapies MM, underlining achieve responses.

Язык: Английский

Rheumatologic complications of CAR-T Cell therapy. Experience of a single center

Seminars in Arthritis and Rheumatism, Год журнала: 2024, Номер 71, С. 152610 - 152610

Опубликована: Дек. 27, 2024

Язык: Английский